Barinthus Biotherapeutics (BRNS) AI Stock Analysis

• Market Cap: $28.58M
• Dividend Yield: N/A
• Average Volume (3M): 124.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.03
• Revenue Growth: -100.00%
• EPS Growth: -26.30%
• Country: US
• Employees: 105
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 40,830,353
• 10 Day Avg. Volume: 97,530
• 30 Day Avg. Volume: 124,726
• PEG Ratio: 0.04
• Price to Book (P/B): 0.37
• Price to Sales (P/S): 3.18
• P/FCF Ratio: -1.60
• Enterprise Value/Market Cap: -1.19
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.49
• 1Y Price Target: $4.00
• Price Target Upside: 426.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.71 ▼(-7.24% Downside)

The score is driven primarily by weak financial performance (no TTM revenue, large losses, and ongoing cash burn). Technicals add pressure with a below-long-term-average price and negative MACD, while corporate events are mixed—Nasdaq bid-price non-compliance is a major risk despite encouraging early clinical-trial progress.

Positive Factors

Modest leverage

Low debt-to-equity (~0.14) gives the company durable financial flexibility to fund R&D and operations without immediate pressure from interest or near-term maturities. This reduces short-term refinancing risk and supports pursuing clinical programs while losses persist.

Positive Phase 1 safety signal

A well-tolerated SAD readout with dose-dependent pharmacology materially de-risks the VTP-1000 program over the coming months. Durable clinical progress supports continued development, potential partner interest, and a clearer regulatory path for an antigen-specific celiac therapy.

Multiple funding/revenue channels

A diversified mix of product revenue, collaborations, licensing, milestone payments and grants reduces reliance on a single cash source. Structurally this supports multiple non-dilutive funding options and partnership-led development, important during prolonged clinical stages.

Negative Factors

No TTM revenue and large losses

Absence of trailing revenue combined with substantial recurring losses indicates limited internal ability to self-fund operations. Over months this heightens dependence on external capital, increases dilution risk, and signals weak near-term earnings visibility for sustainable operations.

Sustained cash burn

Consistent negative operating and free cash flow points to ongoing consumption of cash to support R&D and SG&A. Persisting cash burn raises structural financing needs, may constrain program funding or commercialization investments, and elevates pressure to raise capital.

Nasdaq minimum bid-price non-compliance risk

A formal Nasdaq non-compliance notice creates a material corporate governance and access-to-capital risk. Potential delisting or a reverse split can affect liquidity, institutional interest, and ability to raise funds or execute partnerships over the medium term.

Barinthus Biotherapeutics Business Overview & Revenue Model

Company Description

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

How the Company Makes Money

Barinthus Biotherapeutics generates revenue through multiple key streams, primarily from the sale of its biotherapeutic products, which are developed for specific medical conditions. The company also engages in collaborative partnerships with larger pharmaceutical firms, which may involve licensing agreements, co-development deals, and research funding. Additionally, BRNS may receive milestone payments and royalties based on the successful advancement of its products through various stages of clinical development and eventual commercialization. Grants and government funding for research initiatives further supplement the company's earnings, enabling it to innovate and expand its product pipeline.

Barinthus Biotherapeutics Financial Statement Overview

Summary

Overall fundamentals are weak: TTM revenue is $0 with deeply negative profitability (EBIT about -$82.4M; net income about -$75.9M) and persistent cash burn (TTM operating cash flow about -$30.7M; free cash flow about -$31.0M). A key offset is modest leverage (debt-to-equity ~0.14), but declining equity/assets and ongoing losses raise financing risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is $0 with a sharp decline versus the prior year, and profitability remains deeply negative (EBIT about -$82.4M; net income about -$75.9M). While 2024 showed meaningful revenue ($15.0M) and 2022 briefly reached profitability, results have since deteriorated into sustained losses, highlighting high ongoing spend relative to revenue and limited near-term earnings visibility.

Balance Sheet

Leverage appears modest with low debt relative to equity (debt-to-equity ~0.14 in TTM (Trailing-Twelve-Months)), providing financial flexibility. However, equity and total assets have trended down materially from 2021–2023 levels, and returns on equity are strongly negative in recent periods, signaling ongoing value erosion driven by continued net losses.

Cash Flow

Cash generation is weak: TTM (Trailing-Twelve-Months) operating cash flow is about -$30.7M and free cash flow is about -$31.0M, indicating continued cash burn. Free cash flow has been consistently negative across years and worsened versus the prior period, which increases reliance on external funding despite free cash flow tracking net losses relatively closely.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	14.97M	802.00K	44.70M	268.00K	4.82M
Gross Profit	0.00	14.97M	802.00K	44.70M	268.00K	-9.57M
EBITDA	-69.35M	-55.37M	-71.06M	5.19M	-47.87M	-16.56M
Net Income	-75.88M	-61.07M	-73.35M	5.34M	-50.87M	-17.71M
Balance Sheet
Total Assets	109.20M	160.33M	214.51M	270.20M	280.71M	50.67M
Cash, Cash Equivalents and Short-Term Investments	74.27M	110.66M	142.09M	194.38M	214.05M	43.27M
Total Debt	11.57M	12.01M	12.98M	8.77M	7.22M	46.36M
Total Liabilities	24.64M	30.19M	27.51M	27.00M	28.15M	53.81M
Stockholders Equity	84.47M	130.03M	186.78M	242.90M	252.13M	-3.54M
Cash Flow
Free Cash Flow	-30.97M	-29.83M	-56.34M	-20.57M	-33.73M	-11.32M
Operating Cash Flow	-30.65M	-28.94M	-50.92M	-14.43M	-32.58M	-11.03M
Investing Cash Flow	136.00K	-892.00K	-5.41M	-5.75M	-12.91M	-293.00K
Financing Cash Flow	839.00K	2.16M	1.87M	325.00K	222.74M	41.44M

Barinthus Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRNS, the sentiment is Negative. The current price of 0.76 is above the 20-day moving average (MA) of 0.73, above the 50-day MA of 0.72, and below the 200-day MA of 1.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.43 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRNS.

Barinthus Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALXO	61 Neutral	$108.98M	-0.99	-118.95%	―	―	31.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLGN	48 Neutral	$20.47M	-1.58	-92.74%	―	280.77%	32.82%
BOLD	45 Neutral	$23.50M	-0.38	-44.88%	―	―	-0.50%
BRNS	44 Neutral	$28.58M	-0.37	-62.30%	―	-100.00%	-26.30%
ALGS	42 Neutral	$43.51M	-0.36	-141.82%	―	-55.88%	6.14%
GDTC	42 Neutral	$9.97M	-3.53	-42.29%	―	―	-21.99%

Barinthus Biotherapeutics Corporate Events

Barinthus Biotherapeutics Receives Nasdaq Minimum Bid Price Notice

On December 30, 2025, Barinthus Biotherapeutics plc received a notice from Nasdaq that the closing bid price of its American Depositary Shares had remained below $1.00 for 30 consecutive business days, placing the company out of compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market. While the ADSs remain listed and trading is unaffected in the near term, Barinthus now has until June 29, 2026, to restore its share price to at least $1.00 for ten consecutive business days or risk potential delisting, and the company is monitoring its stock performance and considering options such as a reverse stock split to regain compliance, which could have implications for existing shareholders and the company’s market standing.

The most recent analyst rating on (BRNS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Barinthus Biotherapeutics stock, see the BRNS Stock Forecast page.

Barinthus Biotherapeutics Updates on AVALON Trial Progress

On December 10, 2025, Barinthus Biotherapeutics announced an update on its Phase 1 AVALON clinical trial for VTP-1000, an antigen-specific immunotherapy for celiac disease. The single ascending dose portion of the trial showed that VTP-1000 was well-tolerated with no serious adverse events and demonstrated a dose-dependent pharmacological effect. The ongoing multiple ascending dose portion, which includes a gluten challenge, is expected to provide further insights in the second half of 2026. This development marks a significant step in addressing the unmet needs in celiac disease treatment, potentially positioning Barinthus Bio as a leader in immune tolerance therapies.

The most recent analyst rating on (BRNS) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Barinthus Biotherapeutics stock, see the BRNS Stock Forecast page.